Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Abstract GSK3640254 (GSK'254) is a novel HIV‐1 maturation inhibitor with pharmacokinetics supporting once‐daily (QD) therapy for HIV‐1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac repolarization. In this two‐part, randomized study, healthy...
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Wiley
2023-12-01
|
| Sarja: | Pharmacology Research & Perspectives |
| Aiheet: | |
| Linkit: | https://doi.org/10.1002/prp2.1151 |